← Human Trials & Peer-Reviewed Studies
Effects of B-type natriuretic peptide on cardiovascular biomarkers in healthy volunteers
Plain-language guide to PMID 25539929 (2015): single-blind randomized controlled trial study of BNP (Nesiritide).
Key Facts
- PMID
- 25539929
- Journal
- Journal of applied physiology (Bethesda, Md. : 1985)
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Resl M et al. (9 authors)
- DOI
- 10.1152/japplphysiol.00101.2014
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
Cardiovascular biomarkers provide independent prognostic information in the assessment of mortality and cardiovascular complications.
However, little is known about possible interactions between these biomarkers.
Who Took Part
The age groups tagged for this paper are young adults and adults, men only.
How the Study Was Run
The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Only one side, usually the participants, was kept unaware of whether BNP (Nesiritide) was given.
The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.
In the crossover set-up each of the participants took both BNP (Nesiritide) and the comparison in turn, acting as their own control.
What Was Measured
Cardiovascular biomarkers provide independent prognostic information in the assessment of mortality and cardiovascular complications.
In the present study, the researchers evaluated the influence of B-type natriuretic peptide (BNP) on midregional-proadrenomedullin (MR-proADM), C-terminal-proendothelin-1 (CT-proET-1), growth differentiation factor-15 (GDF-15), midregional-proatrial natriuretic peptide (MR-proANP), copeptin, and procalcitonin in healthy volunteers.
Topics PubMed links to this paper include Adrenomedullin, Atrial Natriuretic Factor, Biomarkers, Calcitonin, Calcitonin Gene-Related Peptide, Cardiovascular System and Endothelin-1.
Author keywords: BNP, cardiovascular biomarkers, healthy volunteers and multimarker approaches.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of BNP (Nesiritide).
The publication is from 2015 (Journal of applied physiology (Bethesda, Md. : 1985)), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.